Market Cap (In USD)
4.35 Billion
Revenue (In USD)
-
Net Income (In USD)
-85.89 Million
Avg. Volume
10.49 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 8.79-99.295
- PE
- -
- EPS
- -
- Beta Value
- 0.994
- ISIN
- US92686J1060
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Dr. Brian Lian Ph.D.
- Employee Count
- -
- Website
- https://www.vikingtherapeutics.com
- Ipo Date
- 2018-10-08
- Details
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
More Stocks
-
SWEC-BSweco AB (publ)
SWEC-B
-
ZYDUSWELLZydus Wellness Limited
ZYDUSWELL
-
0HR2CME Group Inc.
0HR2
-
6139
-
4153
-
HSTCHST Global, Inc.
HSTC
-
ASTRALAstral Limited
ASTRAL
-
AHCHY